1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …

Background Direct oral anticoagulants (DOACs) and warfarin are usually used for people
with atrial fibrillation (AF). However, for the AF patients at risk of falling, the effectiveness and …

Chronic kidney disease (CKD) is associated with a higher risk of atrial fibrillation (AF). The
mechanistic link between CKD and AF remains elusive. IL-1β, a main effector of NLR family …

In atrial fibrillation (AF), lower risks of death and bleeding with non-vitamin-K oral
anticoagulants (NOACs) were reported in meta-analyses of controlled trials, but whether …

Background Only 50% of atrial fibrillation (AF) patients recommended for oral
anticoagulation (OAC) use these medications, and less than half of them adhere to OAC. In …

Background Asymptomatic atrial fibrillation is often detected incidentally. Prognosis and
optimal therapy for asymptomatic compared with symptomatic atrial fibrillation is uncertain …

Aims To determine whether the Global Anticoagulant Registry in the FIELD–Atrial Fibrillation
(GARFIELD-AF) integrated risk tool predicts mortality, non-haemorrhagic stroke/systemic …

Atrial fibrillation (AF), the most common arrhythmia in clinical practice, is associated with an
increase in mortality and morbidity due to its high potential to cause stroke and systemic …

The Global Anticoagulant Registry in the Field-Atrial Fibrillation (GARFIELD-AF) examined
real-world practice in a total of 57,149 (5069 retrospective, 52,080 prospective) patients with …

Aims The risk of adverse events in atrial fibrillation (AF) patients was commonly stratified by
risk factors or clinical risk scores. Risk factors often do not occur in isolation and are often …